Cargando…
Efficacy and Safety of OnabotulinumtoxinA 400 Units in Patients with Post-Stroke Upper Limb Spasticity: Final Report of a Randomized, Double-Blind, Placebo-Controlled Trial with an Open-Label Extension Phase
In many countries, 400 units (U) is the maximum dose of onabotulinumtoxinA available to treat upper limb spasticity, but few studies have demonstrated the optimal use of this dose. In the double-blind phase of this randomized, controlled trial, we compared the efficacy and safety of 400 vs. 240 U on...
Autores principales: | Abo, Masahiro, Shigematsu, Takashi, Hara, Hiroyoshi, Matsuda, Yasuko, Nimura, Akinori, Yamashita, Yoshiyuki, Takahashi, Kaoru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077183/ https://www.ncbi.nlm.nih.gov/pubmed/32085529 http://dx.doi.org/10.3390/toxins12020127 |
Ejemplares similares
-
OnabotulinumtoxinA Reduces Temporal Pain Processing at Spinal Level in Patients with Lower Limb Spasticity
por: De Icco, Roberto, et al.
Publicado: (2019) -
Rehabilitation plus OnabotulinumtoxinA Improves Motor Function over OnabotulinumtoxinA Alone in Post-Stroke Upper Limb Spasticity: A Single-Blind, Randomized Trial
por: Devier, Deidre, et al.
Publicado: (2017) -
Treatment of adult spasticity with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Esquenazi, Alberto, et al.
Publicado: (2023) -
Efficacy and safety of onabotulinumtoxinA with standardized occupational therapy for treatment of pediatric upper limb spasticity: Phase III placebo-controlled randomized trial
por: Dimitrova, Rozalina, et al.
Publicado: (2021) -
Long‐Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity
por: Esquenazi, Alberto, et al.
Publicado: (2021)